Ferrous Ascorbate 30mg + Folic Acid 550mcg/5ml Suspension is a liquid pharmaceutical formulation containing Ferrous Ascorbate and Folic Acid in defined quantities per 5ml of the finished suspension. Developing a suspension containing mineral and vitamin components requires careful control of particle characteristics, dispersion, viscosity, sedimentation behavior, preservative system, and dose uniformity. For pharmaceutical companies expanding their liquid formulation portfolio, this product can be incorporated into a structured PCD Pharma Franchise range supported by appropriate manufacturing specifications and quality documentation.
The formulation contains Ferrous Ascorbate 30mg and Folic Acid 550mcg per 5ml. Since the two ingredients have different physicochemical characteristics, the formulation development process requires evaluation of their compatibility, solubility behavior, particle characteristics, and stability within the selected liquid vehicle.
A suspension system generally requires suitable suspending agents to maintain uniform distribution of dispersed particles throughout the formulation. Other excipients may include purified water, sweetening agents, flavoring components, viscosity modifiers, wetting agents, stabilizers, and preservatives where appropriate.
The choice and concentration of these excipients are established during formulation development. The objective is to obtain a formulation with acceptable viscosity, controlled sedimentation, suitable dispersibility, and consistent distribution of the formulation components.
Pre formulation studies can evaluate parameters such as particle size, zeta potential where relevant, sedimentation behavior, viscosity, pH, and compatibility between Ferrous Ascorbate, Folic Acid, and the selected excipient system.
For a suspension formulation, particle characteristics have a direct influence on physical stability. Ferrous Ascorbate and other dispersed components may require appropriate particle-size control before incorporation into the liquid vehicle.
Raw materials can undergo suitable milling, sieving, or other controlled processing depending on their specifications. Consistent particle size can help support uniform dispersion and reduce excessive sedimentation.
Wetting of the dispersed material may be carried out using suitable pharmaceutical excipients before incorporation into the main vehicle. This can help minimize floating, clumping, or localized aggregation of particles.
The suspending system is prepared under controlled mixing conditions. The concentration of viscosity-modifying and suspending ingredients is established according to the formulation specification to achieve the desired flow characteristics.
Folic Acid is present at a comparatively lower concentration than Ferrous Ascorbate, so controlled incorporation and uniform distribution are important considerations. The manufacturing process should be designed to maintain consistent composition throughout the bulk suspension.
Manufacturing begins with the identification, dispensing, and verification of all raw materials according to the approved batch formula. The liquid vehicle may be prepared separately, with water-soluble excipients dissolved under controlled conditions.
Suspending agents may require controlled hydration or dispersion before the addition of active ingredients. Adequate mixing time is allowed for the formation of a consistent suspension base.
Ferrous Ascorbate is incorporated using an established addition sequence, followed by Folic Acid and other formulation components as specified. Agitation speed and mixing duration are controlled to promote uniform dispersion.
Depending on the formulation design, homogenization may be used to improve particle distribution and minimize localized concentration differences. Excessive processing, however, should be avoided where it could negatively influence the physical characteristics of the formulation.
Parameters such as pH, temperature, mixing speed, viscosity, and processing time may be monitored during production. In-process samples can be collected from predefined locations to assess uniformity.
Before filling, the bulk suspension may undergo suitable filtration or screening where compatible with the product design. The finished bulk is then transferred to the filling area under controlled conditions.
Finished-product testing for Ferrous Ascorbate 30mg + Folic Acid 550mcg/5ml Suspension includes evaluation of both chemical and physical quality attributes. Identification and assay procedures can be used to confirm the presence and specified concentration of Ferrous Ascorbate and Folic Acid.
Because the formulation is a suspension, physical uniformity is an important quality characteristic. Testing may include assessment of sedimentation volume, dispersibility, viscosity, particle distribution, and homogeneity according to the established product specification.
pH, appearance, color, odor, fill volume, and specific gravity may also be evaluated where relevant. Microbial quality testing is important for aqueous liquid formulations, with the preservation system assessed according to the formulation and applicable specifications.
Dose uniformity can be evaluated through appropriate sampling and analytical procedures to verify consistency between different portions of the batch. The sampling methodology should account for the possibility of particle settling during handling.
Analytical methods should be suitably validated or qualified for the formulation matrix. Laboratory equipment should be maintained, calibrated, and operated according to documented procedures.
All test results and observations are recorded in the batch quality documentation before final product release.
Stability studies are performed to evaluate the ability of Ferrous Ascorbate 30mg + Folic Acid 550mcg/5ml Suspension to maintain its defined quality characteristics throughout the proposed shelf life.
Samples may be evaluated for assay, pH, viscosity, appearance, sedimentation, dispersibility, microbial quality, and other relevant physical and chemical parameters. Special attention is given to changes in particle distribution and sediment characteristics during storage.
A suitable suspension should demonstrate controlled settling behavior and the ability to redisperse according to the established product specification. Stability studies help determine whether the selected suspending system remains effective throughout the intended storage period.
Packaging development includes selection of suitable pharmaceutical-grade bottles and compatible closures. Container compatibility studies may assess interaction between the suspension and packaging material, leakage, closure integrity, and physical protection.
The bottle should support consistent handling and facilitate appropriate product withdrawal. The final pack should contain approved product information including composition, strength, batch details, manufacturing information, expiry information, storage conditions, and other applicable labeling requirements.
Ferrous Ascorbate 30mg + Folic Acid 550mcg/5ml Suspension can be incorporated into a diversified liquid pharmaceutical portfolio through standardized formulation development and controlled manufacturing practices. For companies operating within the PCD Pharma Franchise sector, maintaining consistent specifications for suspension formulations supports organized product management and reliable batch documentation.
A complete product-development file may include raw-material specifications, supplier qualification records, formulation composition, manufacturing instructions, analytical methods, suspension-performance specifications, packaging details, and stability protocols.
Particular attention should be given to maintaining uniformity throughout the production cycle. Controlled particle-size processing, proper wetting, adequate suspension-system hydration, defined mixing parameters, and suitable homogenization can contribute to reproducible manufacturing.
Quality control should continue from incoming raw-material inspection through bulk preparation, in-process testing, filling, packaging, and final batch release. Batch manufacturing records provide traceability for each production lot.
For commercial portfolio management, technical product information should remain consistent across packaging artwork, catalogs, product listings, and other business materials. The stated composition should correspond with the approved formulation and quality documentation.
Overall, Ferrous Ascorbate 30mg + Folic Acid 550mcg/5ml Suspension requires coordinated control over particle characteristics, suspension-system design, active-ingredient dispersion, viscosity, redispersibility, analytical testing, microbial quality, stability, and packaging compatibility. A systematic manufacturing and quality framework across these stages supports the development of a consistent and professionally managed liquid suspension suitable for inclusion in a broader pharmaceutical and PCD Pharma Franchise portfolio.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech